PTC Therapeutics, Inc. (PTCT) Stock Score, Valuation & Financial Research
PTC Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 62/100.
Quick answer for PTCT
PTC Therapeutics, Inc. currently has a Wall Street Score of 62/100. The stored market price is $66.06. Its financial score is 40/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What PTC Therapeutics, Inc. does
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the C
PTCT financial snapshot
- Wall Street Score:
- 62/100
- Current price:
- $66.06
- Market capitalization:
- $5.51B
- Revenue:
- $827.1M
- Net income:
- $-186.7M
- Free cash flow:
- $702.3M
- Cash:
- $834.0M
- Total debt:
- $395.1M
- EPS:
- 8.58
- P/E ratio:
- 7.7x
- Financial score:
- 40/100
- Valuation score:
- 100/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.5%.
- Free cash flow is $702.3M, showing positive cash generation.
- The balance sheet shows $834.0M of cash versus $395.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 40/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PTCT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.